Top entities: Roche, Abbott Laboratories, Siemens — Siemens Healthineers, Danaher Corporation, MSCI Asia Pacific Index.

What category does this event fall under?

Business — classified as market forecast.

What is the sentiment of coverage?

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Fapon Biotech introduced system · Fapon Biotech entered agreement LASCCO · Fapon Biotech entered agreement Abionic SA

Is this event still developing?

This is an active story, last updated Jul 06, 2026. Coverage continues to evolve.

Business market forecast

CLIA Market Forecast to 2031

Q: When did this event occur?

First reported Jun 05, 2026; last updated Jul 06, 2026.

Q: What is the market impact?

General. The global chemiluminescence immunoassay (CLIA) market is projected for significant growth, driven by increasing demand for accurate diagnostic tests for chronic and infectious diseases, and advancements in automation.

Analysis based on 6 articles · First reported Jun 05, 2026 · Last updated Jul 06, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The global chemiluminescence immunoassay (CLIA) market is projected for significant growth, driven by increasing demand for accurate diagnostic tests for chronic and infectious diseases, and advancements in automation. This expansion will benefit major diagnostic companies like Roche, Abbott Laboratories, and Siemens — Siemens Healthineers, particularly in high-growth regions such as MSCI Asia Pacific Index.

Healthcare Biotechnology Medical Devices

Event Summary

The global chemiluminescence immunoassay (CLIA) market is projected to grow from USD 11.58 billion in 2026 to USD 16.39 billion by 2031, at a CAGR of 7.2%. This growth is driven by the rising demand for high-sensitivity diagnostic testing for chronic and infectious diseases, the rapid adoption of automated laboratory systems, and technological advancements like AI-enabled automation and multiplex testing. Consumables are expected to hold the largest market share due to continuous demand, while oncology applications are set to expand significantly. Hospitals will remain the dominant end-user segment, and the MSCI Asia Pacific Index region is anticipated to show the highest growth due to increased healthcare investments and infrastructure development. Key players like Roche, Abbott Laboratories, Siemens — Siemens Healthineers, and Danaher Corporation are strengthening their market positions through innovation and strategic collaborations, such as Fapon Biotech's licensing agreement with LASCCO and Abionic SA for PSP technology in China.

Key Actions

80 Fapon Biotech introduced system

70 Fapon Biotech entered agreement LASCCO

70 Fapon Biotech entered agreement Abionic SA

Entities Involved

stock

Roche

As a leading company in the CLIA market, Roche is strengthening its market position through innovation and strategic collaborations, with its cobas e series platforms playing a major role in advancing high-throughput immunodiagnostic testing globally.

Importance 90.0 Sentiment 70.0

stock

Abbott Laboratories

As a major player in the CLIA market, Abbott Laboratories is strengthening its market position through innovation and strategic collaborations, with its ARCHITECT and Alinity i systems playing a major role in advancing high-throughput immunodiagnostic testing globally.

Importance 90.0 Sentiment 70.0

subs

Siemens — Siemens Healthineers

As a key company in the CLIA market, Siemens — Siemens Healthineers is contributing significantly to market advancements with diverse product offerings and strategies.

Importance 80.0 Sentiment 70.0

stock

Danaher Corporation

As a major company in the CLIA market, Danaher Corporation is strengthening its market position through innovation and strategic collaborations, with its Danaher Corporation — Beckman Coulter DxI systems playing a major role in advancing high-throughput immunodiagnostic testing globally.

Importance 80.0 Sentiment 70.0

index

MSCI Asia Pacific Index

The MSCI Asia Pacific Index region is poised to register the highest CAGR in the CLIA market due to enhanced healthcare systems, increasing healthcare investments, and improved diagnostic service distribution in countries like China, India, and Japan.

Importance 80.0 Sentiment 70.0

stock

DiaSorin

As a significant company in the CLIA market, DiaSorin is contributing significantly to market advancements with diverse product offerings and strategies.

Importance 70.0 Sentiment 70.0

stock

Sysmex Corporation

As a major company in the CLIA market, Sysmex Corporation is strengthening its market positions through innovation, assay menu expansion, workflow automation, and strategic collaborations.

Importance 70.0 Sentiment 70.0

priv

Fapon Biotech

Fapon Biotech entered a licensing agreement with LASCCO and Abionic SA to develop and commercialize PSP technology, integrating it into its chemiluminescent immunoassay analyzer for the Chinese market. Fapon Biotech also introduced the Shine i8000/9000 chemiluminescence immunoassay system.

Importance 70.0 Sentiment 70.0

priv

North American Cobalt Inc.

North American Cobalt Inc. is expected to dominate the global CLIA market in 2025, supported by advanced healthcare infrastructure, strong adoption of automated diagnostic technologies, and high healthcare spending.

Importance 70.0 Sentiment 70.0

cnt

China

China is a key country in the MSCI Asia Pacific Index region, which is witnessing rapid market growth due to increasing healthcare investments and expanding laboratory infrastructure. Fapon Biotech is targeting the Chinese market with its new technology.

Importance 70.0 Sentiment 60.0

stock

Tosoh

Tosoh is a key player in the CLIA market, contributing significantly to market advancements with diverse product offerings and strategies.